June 28, 2023 08:14 AM EDT
FDA+
Manufacturing

FDA plots chal­lenges in im­ple­ment­ing new laws tar­get­ing phar­ma sup­ply chain

Zachary Brennan

Senior Editor

BOSTON — Sev­er­al new laws – en­com­pass­ing the next five years of bio­phar­ma in­dus­try user fees and some add-ons to fed­er­al gov­ern­ment fund­ing – set …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

J&J takes 340B fight with fed­er­al gov­ern­ment to court

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

Ex­clu­sive: Flag­ship names two CEO-part­ners to lead Va­lo Health, Apri­ori Bio

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times